GLP-1 Drug Development: Leveraging Integrated Solutions to Improve Patient Engagement

In this webinar, Audrey Chardonnet and Joe Reynolds explored the expanding role of GLP-1 drugs in treating metabolic diseases such as type 2 diabetes, obesity, and cardiovascular conditions.

For GLP-1 therapies, advanced drug delivery devices play a critical role in improving patient adherence and ensuring treatment success. Aptar Pharma is scaling its capabilities to meet the growing demand for these therapies, both in volume and in the range of its component offerings. Our solutions support the three primary delivery platforms used in this market: autoinjectors, pen injectors, and vial systems. For each, Aptar Pharma provides a comprehensive range of high-quality components designed to ensure compatibility, performance, and a patient-centric experience.

During the session, Audrey shared key success factors for GLP-1 drug developers and how Aptar Pharma can support them in achieving these:

1. Upscaling Supply to commercialization volume:

Aptar Pharma can help pharmaceutical companies in securing their needs with a new state-of-the-art factory in France and a regionalized manufacturing approach to increase market responsiveness.

2. Securing drug compatibility for fast time to market:

Ensuring compatibility with delivery systems is essential for accelerating time-to-market. Aptar Pharma offers a diverse portfolio of vial stoppers, syringe and cartridge plungers, and rigid-needle shields to meet the needs of GLP-1 drug developers. To support compliance with Annex 1 while addressing drug development requirements, our high-quality syringe and cartridge plungers, as well as vial stoppers, are available in PremiumCoat®, PremiumFill® & Ready-to-Use.

3. Differentiation from intensifying competition:

In a competitive market, differentiation is key.  Aptar Pharma empowers its partners with tailored development services, expertise in device selection, and solutions to enhance patient adherence.

To enhance patient engagement, Noble’s program includes:

• Training devices to build patient confidence
• Digital support to engage patients with relevant information
• Real-world evidence generation to support persistence

Finally, Aptar Pharma’s commitment to sustainability stands as a key pillar of differentiation. Pharmaceutical companies can rely on a partner whose manufacturing sites align with rigorous sustainability objectives.

To conclude, Aptar Pharma’s unique 3D value proposition—drug services, device and component solutions, and digital and patient services—offers a fully integrated approach to accelerate drug development, ensure supply security, and enhance patient engagement. This 3D approach positions Aptar Pharma as a key partner in GLP-1 drug development.